

CNMV
Edison, 4
28006 Madrid

Barcelona (Spain), July 22, 2021

OTHER RELEVANT INFORMATION

In accordance with the Article 227 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, **LABORATORIO REIG JOFRE SA** ("Reig Jofre" or "the Company"), submits hereafter press release on the announcement of the acquisition of 49% of the capital of the subsidiary REIG JOFRE UK LTD.

Yours faithfully,

Mr. Adolf Rousaud
Secretary non-director of the Board of Directors

REIG JOFRE ACQUIRES 100% OF REIG JOFRE UK LTD AND CONSOLIDATES ITS PRESENCE IN THE UNITED KINGDOM

Barcelona, Spain, REIG JOFRE, (BME:RJF), a pharmaceutical company listed on the Spanish stock exchange market, reinforces its international investment in the United Kingdom, with the acquisition of 49% of the capital, which the Spanish Company for Development Financing (COFIDES, SA) owned in REIG JOFRE UK LTD, since 2015.

In 2014, Reig Jofre incorporated REIG JOFRE UK LTD to develop its business units in the United Kingdom and advance its strategic plan for international growth.

In 2015, the joint state and privately owned COFIDES, which provides financial support for investment projects of Spanish companies in foreign countries, subscribed 49% of the capital of the company through the State funds for Investments Abroad (FIEX) of the Spanish Ministry of Industry, Trade and Tourism.

COFIDES' support made possible to consolidate Reig Jofre presence in the British market and acquire a portfolio of dermatological medicines, integrated into the *Specialty Pharmacare* division, with widely established brands in the United Kingdom such as **Synalar** and **Metosyn**, used in skin infections, psoriasis or inflammatory conditions such as eczema and dermatitis, as well as **Crystacide**, Hydrogen Peroxide cream, recommended by NICE (National Institute for Clinical Excellence) as first-line treatment for impetigo in Adults and Children.

In 2020, the UK dermatology business accounted for 7% of this range's revenue globally. Around 5 million units per year of the company's topical products are produced in the specialized plant in Malmö, Sweden.

REIG JOFRE UK LTD distributes a range of specialized and hospital only products of the *Pharmaceutical Technologies* division, produced at the beta-lactam antibiotic plants in Toledo and the injectable and lyophilized plants in Barcelona to the National Health System (NHS) via the United Kingdom tendering system.

The fact of operating in the United Kingdom with its own company contributed to a rapid adaptation in 2020 to the regulatory changes resulting from Brexit.



This international investment is added to that made in April, with the creation of the subsidiary REIG JOFRE Sp. Z o.o. in Poland, the eighth market in which Reig Jofre operates directly with its own sales force, which was created to mainly meet the demand for products from the *Specialty Pharmacare* unit and gradually introduce *Consumer Healthcare* lines.

International expansion is one of Reig Jofre's strategic growth pillars. In 2020, 55% of the turnover beyond Spanish borders was generated through its subsidiaries in (United Kingdom, France, Portugal, Belgium, Sweden, Poland, and Singapore), and distribution agreements with more than 130 business partners in more than 70 countries.

Reig Jofre closed 2020 with sales figures of 230 million euros and an EBITDA of 26.5 million euros. The *Pharmaceutical Technologies* (antibiotics and injectables), *Specialty Pharmacare* (osteoarticular and dermatology) and *Consumer Healthcare* (food supplements and ENT) units accounted for 48%, 29% and 23%, respectively.

Receive updated news about Reig Jofre by registering with the company's **subscription centre** via our corporate website: www.reigjofre.com

Further information

Inma Santa-Pau - Director of Communication and Investor Relations - isantapau@reigjofre.com
www.reigjofre.com